The Thermo Fisher Scientific story

What drives the business

• Thermo Fisher has expanded beyond laboratory equipment into drug development services through PPD and Clario, completing the Clario acquisition in March 2026 for $8.875 billion in cash plus potential additional payments to add clinical trial outcome measurement and analysis.
• Its approximately $4.0 billion acquisition of Solventum’s Purification and Filtration business in September 2025 added filtration technologies to Life Sciences Solutions, extending its role in drug manufacturing and adjacent industrial markets.
• Laboratory Products and Biopharma Services, which includes PPD and Clario, accounted for 55.8% of consolidated revenue in the quarter to June 2026.
• Customers include pharmaceutical and biotechnology companies, universities, laboratories and government agencies, while recurring purchases of reagents and plastics help support demand when laboratory equipment budgets are cut.
• New Orbitrap mass spectrometry platforms and the Applied Biosystems PowerFlex Thermal Cycler introduced in the quarter to June 2026 expand its research tools, while a collaboration with Precision Health Research, Singapore combines Olink technology and Orbitrap systems for the PRECISE-SG100K population health study.

What the price assumes

At $678.60, the reverse DCF implies that free cash flow after stock pay grows 15.8% a year for ten years, using a 10.2% discount rate.

That compares with 12.2% annual growth over the last 10 years and the TenQ check’s 8.1% bar, which slows the historical pace halfway toward 4%.

Revenue grew 7.2% over the last twelve months but at a -0.3% annual pace over the last three years, so the cash growth implied by the price exceeds both the historical cash growth record and the recent revenue growth rate.

Value TMO on your own assumptions

What could change the story

• Laboratory equipment demand depends on customer capital budgets and government research funding, leaving orders exposed to spending delays, cancellations and changes in public funding.
• Acquisition integration matters because the acquired businesses must generate the cash flows supporting their purchase prices, while the return on capital employed of 8.3% falls below the TenQ check’s 10.0% bar.
• Total debt of $45.7 billion compares with $4.1 billion in cash and short-term investments, although Thermo Fisher passes 6 of 6 financial health checks and generated $7.3 billion of free cash flow over the last twelve months.
• Tariffs, currency movements and Chinese rules favoring local suppliers could affect demand and costs across its international operations.
• The 2.9% free cash flow yield is below its historical 3.7%, leaving less cash yield at the quoted price if growth or acquisition benefits fall short.

What to watch next

• The July 2026 earnings release deferred updated 2026 financial guidance to the earnings call rather than stating numerical ranges.
• Subsequent releases will show whether organic revenue growth holds near the 5% recorded in the quarter to June 2026 and whether the GAAP operating margin builds on 17.4%.
• Clario’s contribution to Laboratory Products and Biopharma Services will test management’s expectation for high single digit growth and an improvement in Thermo Fisher’s adjusted operating margin.
• Further details on the announced microbiology divestiture, alongside debt, cash generation and capital spending, will clarify how Thermo Fisher balances portfolio changes with funding needs.

Sources

• Thermo Fisher Scientific's earnings release, filed with the SEC
• Its latest 10-Q or 10-K, for the risk factors
• The TMO stock report, for every figure and check